ctDNA quantification improves estimation of outcomes in patients with high grade osteosarcoma: a translational study from the OS2006 trial
To better stratify osteosarcoma patients, investigators developed a new personalized method using circulating tumor DNA (ctDNA) quantification which is obtained from a blood sample. In the publication “ctDNA quantification improves estimation of outcomes in patients with high grade osteosarcoma: a translational study from the OS2006 trial,” plasma from patients was tested for the amount of ctDNA at diagnosis, before surgery, and at the end of treatment. The different levels of ctDNA were then used to develop a prediction tool that includes the ctDNA quantification in addition to known clinical parameters to estimate patients’ individual risk. The ctDNA quantification at diagnosis (diagCPA) was found to be a strong prognostic factor of relapse risk. An additional trial is currently being conducted to confirm these results.